Skip to main content
. 2018 Feb 15;4(4):529–536. doi: 10.1001/jamaoncol.2017.5314

Figure 2. Kaplan-Meier Estimates of Progression-Free Survival and Overall Survival, According to Treatment Arm.

Figure 2.

Arm A comprises 59 patients receiving a modified schedule of fluorouracil, oxaliplatin, and irinotecan hydrochloride (mFOLFOXIRI) plus cetuximab followed by maintenance with cetuximab. Arm B comprises 57 patients receiving mFOLFOXIRI plus cetuximab followed by maintenance with bevacizumab. HR indicates hazard ratio; NE, not estimable.